The role and possible molecular mechanism of valproic acid in the growth of MCF-7 breast cancer cells

Aim To investigate the role of valproic acid (VPA), a class I selective histone deacetylase inhibitor, on Michigan Cancer Foundation (MCF)-7 breast cancer cells, named and explore its possible molecular mechanism.

Methods MCF-7 cells were cultured with sodium valproate (0.5-4.0 mmol/L) for 24 h, 48 h, and 72 h in vitro, respectively. The cell viability, apoptosis, and cell cycle were examined. The activities and protein expressions of caspase-3, caspase-8, and caspase-9 were subsequently assayed. Finally, mRNA and protein expressions of cyclin A, cyclin D1, cyclin E, and p21 were analyzed.

Results Sodium valproate suppressed MCF-7 cell growth, induced cell apoptosis, and arrested G1 phase in a time- and concentration-dependent manner, with the relative cell viabilities decreased, cell apoptosis ratios increased, and percentage of G1 phase enhanced (P < 0.05). Increased activity of caspase-3 and caspase-9, but not caspase-8, and increased protein levels were found under sodium valproate (2.0 mmol/L, 48h). P21 was up-regulated and cyclin D1 was down-regulated at both mRNA and protein levels under sodium valproate (2.0 mmol/L, 48h)(P< 0.05), although cyclin E and cyclin A remained unchanged.

Conclusion These results indicate that VPA can suppress the growth of breast cancer MCF-7 cells by inducing apoptosis and arresting G1 phase. Intrinsic apoptotic pathway is dominant for VPA-induced apoptosis. For G1 phase arrest, p21 up-regulation and down-regulation of cyclin D1 may be the main molecular mechanism.

Received: May 9, 2017
Accepted: October 2, 2017
Correspondence to:
Xia Zhao
Department of Laboratory Medicine
Shandong Provincial Qianfoshan Hospital
Shandong University
Jinan, Shandong 250014
P. R. China
zhaoxia699@163.com
Histone acetylation is dynamically regulated by histone acetyltransferase (HAT) and histone deacetylase (HDAC). HATs lead to the relaxation of chromatin structures and genes transcriptional activation, whereas HDACs are associated with chromatin condensation and transcriptional silence (1,2). Alterations in eukaryotic chromatin structures caused by acetylation of the core histone N-terminal domains seem to play a central role in the regulation of gene transcription. Recent studies have demonstrated the correlation between histone acetylation or deacetylation and the genesis and development of some types of tumors (3-5). Thus, a new approach to tumor therapy emerged: activation of HATs and/or suppression of HDACs.

Histone deacetylase inhibitors (HDACIs), such as sodium butyrate (6), apicidin (7), and trichostatin A (8), showed antitumor functions, including cell growth inhibition, apoptosis induction, tumor cell re-differentiation stimulation, and cell cycle arrest induction in G1 phase. Valproic acid (VPA), which has been used widely as an anticonvulsant for over 20 years and has been well known for its low noxious and prolonged effectiveness (9), was demonstrated as a class I selective histone deacetylase inhibitor (10). Multiple antiproliferative effects of VPA resulting from inhibition of deacetylase activity were reported in various malignancies, such as human choriocarcinoma (11), thyroid cancer (12), hepatic cancer (13), pancreatic cancer (14), breast cancer (15), and so on. Various gene expression changes were further proved under inhibition of deacetylase activity, including up-regulation of multiple cyclin-dependent kinase inhibitors and down-regulation of cyclins, nuclear receptors, and p53 (16). A similar study in oral squamous cell carcinoma (OSCC) showed that treatment with VPA increased the cells distributed in G1 phase and reduced cells in the S phase of human tongue squamous cell carcinoma cells CAL-27 (17). However, further studies for VPA’s anti-tumor function and molecular mechanism are still needed, especially in breast cancer (18,19), which occurs at high incidence in China.

The aim of the present study was to investigate the role of VPA on cultured MCF-7 cells, a typical breast cancer cell line, and further explore its possible molecular mechanism, particularly in cell apoptosis and cell cycle. Our hypothesis was that VPA could inhibit the growth of Michigan Cancer Foundation (MCF)-7 by inducing cell apoptosis and affecting its cell cycle. Our data showed that VPA suppressed MCF-7 growth, induced apoptosis, and arrested G1 phase. Intrinsic apoptotic pathway is dominant in VPA-induced apoptosis, and p21 up-regulation and down-regulation of cyclin D1 may be the main molecular mechanism for G1 phase arrest.

MATERIALS AND METHODS

Reagents

The human breast cancer cell line MCF-7 was obtained from the American Type Culture Collection (ATCC). Gibco media RPMI 1640 and fetal bovine serum (FBS) were used (Invitrogen Co., Carlsbad, CA, USA). Anti-caspase-3, cleaved caspase-3, caspase-9, cleaved caspase-9, caspase-8, cleaved caspase-8, and p21Waf/cip1 (below as p21) antibodies were obtained from Cell Signaling Technology (Boston, MA, USA). Anti-cyclin A, cyclin D1, cyclin E, and β-actin antibodies were purchased from Santa Cruz Biotechnology (Cambridge, UK). Sodium valproate, Cell Counting Kit-8 (CCK-8), cell apoptosis related reagents, cell cycle detection reagents, and all other reagents used in the present study were all Sigma products (St. Louis, MO, USA).

Cell culture and VPA exposure treatment

MCF-7 cells (1.0 × 10⁵/mL) were cultured in 10% FBS-1640 medium, with 100 U/mL penicillin and 100 mg streptomycin at 37şC in a humidified atmosphere composed of 95% air and 5% CO₂. For VPA exposure experiment, cells were divided into control and VPA treatment groups. The control cells were cultured as common and equal amounts of phosphate buffered saline (PBS) were added to both groups of cells. For VPA treatment groups, different concentrations of sodium valproate (0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, and 4.0 mmol/L) were added into the medium when cells reached 70%-80% of confluence, with different exposure times (24 h, 48 h, and 72 h).

The relative cell viability detection under CCK-8

Cells (1.0 × 10⁵/mL) were subcultured in a 96-well cell culture cluster (Corning Inc., Corning, NY, USA) (100μL/well), and each sodium valproate concentration group was set to four replicates. CCK-8 (10 μL) was added into each well 1-4 h before the indicated time points. After 1-4 h of incubation at 37şC, the optical density (OD) values were measured at 535 nm using an ELISA reader (Multiskan GO, Thermo Scientific, MA, USA). Relative cell viability was calculated according to the following formula:

Relative cell viability (%) = (ODVPA-ODblank) / (ODcontrol-ODblank) × 100%
Cell apoptosis analysis based on flow cytometry

Cells were trypsinized and collected at the indicated time points as common. As described in the instructions, cells (1.0 × 10⁶/group) were suspended in 200 μL binding buffer containing Annexin V/FITC (5 μL) and PI (10 μL) for 15 minutes at room temperature. Then binding buffer (300 μL) was added into the tube for further detection by flow cytometry (Becton Dickinson, Mountain View, CA, USA). All experiments were performed in triplicate.

Assessment of cell cycle

Cells were trypsinized and collected at the indicated time points as common. After washing twice by cool PBS, cells (1.0 × 10⁶/group) were fixed in 75% frozen ethanol at -20 °C for 1 hour. Cells were then suspended in 200-500 μL cool PBS and, after 20 μL of solution A were added, incubated in a water bath at 37 °C for 30 minutes as described in the instructions. Then 400 μL of solution B were added, and cells were incubated for 30-60 minutes at 4 °C, avoiding light. Results were analyzed by flow cytometry (FACSCanto™ II, Becton Dickinson, NJ, USA). All experiments were performed in triplicate. Further cell cycle analysis was conducted based on ModFit LT software.

Reverse transcription-polymerase chain reaction (RT-PCR) detection

Total RNA was extracted using TRIzol (Invitrogen) as common (20). Reverse transcription was performed using the cDNA synthesis kit in a final volume of 20 μL containing 3 μg total RNA, and 1 μL Oligo (dt) 18 Primer (0.5 μg/μL). PCR was conducted according to the instructions of Takara Taq™. The general amplification conditions were 94°C, 5 minutes; 94°C, 45 seconds; 56 ~ 61.5°C, 45 seconds; 72°C, 45 seconds; 30-35 cycles. Proper volume of the amplified product was subjected to 1% agarose gel for electrophoresis. All experiments were performed in triplicate. The relative optic density (OD) ratio was calculated with the NIH ImageJ software in comparison with β-actin. The primers were designed using Primer 5.0 Software (Table 1).

Western blot analysis

Total protein was extracted using radio immunoprecipitation assay (RIPA) and was quantified using a BCA kit (Sigma) according to the manufacturer’s instructions. Samples (80 μg of total protein each) were used in Western blot analysis with the first antibodies (caspase-3 1:1000, cleaved caspase-3 1:1000, cleaved caspase-9 1:1000, caspase-8 1:1000, and cleaved caspase-8 1:1000, cyclin A 1:200, cyclin D1 1:200, cyclin E 1:200, p21 1:1000, and β-actin 1:2000). The relative OD ratio was calculated with the NIH ImageJ software in comparison with β-actin from three experiments.

Statistical analysis

Data were presented as mean± standard deviation (SD). Normality test was performed using Kolmogorov-Smirnov test. One-way analysis of variance (ANOVA) was applied to analyze these data. For post hoc test, Student-Newman-Keuls method was chosen. Pearson correlation analysis was applied to analyze the correlation between sodium valproate exposure time or concentration and the relative cell viabilities of MCF-7. P values less than 0.05 were considered statistically significant. Statistical calculations were performed using the SPSS 16.0 software package (SPSS Inc., Chicago, IL, USA).

RESULTS

VPA exposure inhibited the growth of MCF-7 cells

The relative cell viabilities of MCF-7 exposed to sodium valproate (0.5 ~ 4.0 mmol/L) for 24 h, 48 h, and 72 h decreased in a concentration- and time-dependent manner (Figure 1). Taken the relative cell viabilities of control MCF-7 (sodium valproate 0 mmol/L) as 100%, the relative cell viabilities of MCF-7 under sodium valproate exposure time or concentration and the relative cell viabilities of MCF-7. P values less than 0.05 were considered statistically significant. Statistical calculations were performed using the SPSS 16.0 software package (SPSS Inc., Chicago, IL, USA).

Statistical analysis

Data were presented as mean± standard deviation (SD). Normality test was performed using Kolmogorov-Smirnov test. One-way analysis of variance (ANOVA) was applied to analyze these data. For post hoc test, Student-Newman-Keuls method was chosen. Pearson correlation analysis was applied to analyze the correlation between sodium valproate exposure time or concentration and the relative cell viabilities of MCF-7. P values less than 0.05 were considered statistically significant. Statistical calculations were performed using the SPSS 16.0 software package (SPSS Inc., Chicago, IL, USA).

RESULTS

VPA exposure inhibited the growth of MCF-7 cells

The relative cell viabilities of MCF-7 exposed to sodium valproate (0.5 ~ 4.0 mmol/L) for 24 h, 48 h, and 72 h decreased in a concentration- and time-dependent manner (Figure 1). Taken the relative cell viabilities of control MCF-7 (sodium valproate 0 mmol/L) as 100%, the relative cell viabilities of MCF-7 under sodium valproate exposure (2.0 mmol/L, 24 h) were 68.9 ± 6.2% and significantly decreased (P < 0.05). For 48 h, the statistical decrease of relative cell viabilities was significant (P < 0.05).
ties of MCF-7 could be found from sodium valproate (1.5 mmol/L), and from sodium valproate (1.0 mmol/L) for 72 h exposure ($P < 0.05$). Pearson correlation analysis showed that sodium valproate inhibited the growth of MCF-7 cells in a concentration- and time-dependent manner ($r = 0.825$ and $r = 0.416$, respectively, $P < 0.001$ for both).

**VPA exposure induced apoptosis of MCF-7 cells under flow cytometry**

Cell apoptosis was analyzed using flow cytometry after different concentrations of sodium valproate (0.5-4.0 mmol/L) were added into the culture medium of MCF-7 cells. In the control group, the apoptosis showed no statistical changes with the extension of cell culture time, but different levels of increased apoptosis could be found under sodium valproate (Figure 2). For example, the apoptosis in the control cell group after 24 h, 48 h, and 72 h was 0.83 ± 0.19%, 1.62 ± 0.35%, and 2.76 ± 0.25%, respectively, whereas the apoptosis in the cell group exposed to 2.0 mmol/L sodium valproate for 24 h, 48 h, and 72 h was 4.61 ± 0.47%, 8.32 ± 0.75%, and 11.74 ± 0.95%, respectively (Figure 2A). There were also general changes in cell apoptosis under different concentrations of sodium valproate for 24 h, 48 h, and 72 h (Figure 2B). Pearson correlation analysis showed that the apoptosis of MCF-7 was positively correlated with sodium valproate concentrations ($r = 0.925$, $P < 0.001$).

The G1 phase of cells cycle was arrested under VPA exposure

In cultured MCF-7 control cells, G1 phase, S phase, and G2 phase could be detected successively without obvious changes in the ratios of each phase with the extension of cell culture time. In sodium valproate-exposed cells, G1 phase was arrested at different degrees (Figure 3). The means of G1 phase in control cells cultured for 24 h, 48 h, and 72 h were 55.3 ± 1.98%, 54.86 ± 2.19%, and 55.44 ± 2.42%, respectively (Figure 3A). In cells exposed to 2.0 mmol/L sodium valproate, the median G1 phases after 24 h, 48 h, and 72 h were 62.3 ± 4.18%, 64.35 ± 4.57%, and 65.07 ± 3.19%, ie, statistically higher than that of control ($P < 0.05$). All changes of G1 phase in different sodium valproate-exposed cell groups are presented in Figure 3B. For cells exposed to 2.0 mmol/L sodium valproate for 24 h and 48 h, statistically significant G1 arrest could be observed ($P < 0.05$), as well as for cells exposed to sodium valproate 1.5 mmol/L ($P < 0.05$).

**FIGURE 1.** Valproic acid (VPA) exposure decreased the relative cell viabilities of Michigan Cancer Foundation (MCF)-7 in a time- and concentration-dependent manner.

**FIGURE 2.** Cell apoptosis was induced under valproic acid (VPA). A. Flow cytometry showed increased apoptosis of Michigan Cancer Foundation (MCF)-7 cells under sodium valproate (2.0 mmol/L) for 24 h, 48 h, and 72 h. B. Cell apoptosis ratios were increased in a sodium valproate time- and concentration-dependent manner.
Caspase-9 and caspase-3 involved in the VPA-induced apoptosis

To explore the molecular mechanism involved in VPA-induced MCF-7 cells apoptosis, we further investigated the activity and protein expressions of caspase-3, caspase-8, and caspase-9 under sodium valproate (2.0 mmol/L, 48 h) based on Western blot analysis (Figure 4). Both caspase-3 and cleaved caspase-3 (Figures 4A and 4B), caspase-9 and cleaved caspase-9 (Figures 4C and 4D) were significantly up-regulated in comparison with control (P < 0.05). Taking the relative protein expressions of control group as 100%, the levels of caspase-3, cleaved caspase-3, caspase-9, and cleaved caspase-9 were 289.20 ± 24.02%, 297.70 ± 26.75%, 155.34 ± 12.99%, and 148.49 ± 15.13%, respectively. However, for caspase-8 expression, no significant change was observed in sodium valproate-exposed cell group (Figures 4E and 4F).

mRNA and protein expressions of cell cycle-related proteins

The mRNA and protein expression levels of cell cycle-related proteins, including cyclin A, cyclin D1, cyclin E, and...
p21, were analyzed by RT-PCR and Western blot (Figure 5). After sodium valproate (2.0 mmol/L, 48 h) treatment, the mRNA levels of cyclin D1 decreased and p21 significantly increased (P < 0.05), but no significant changes were found in cyclin A and cyclin E levels (Figure 5A). For protein expressions, both cyclin D1 and p21 showed similar changes to mRNA, with cyclin D1 being down-regulated and p21 up-regulated. Cyclin A and cyclin E protein levels showed no statistically significant changes (Figures 5B and 5C).

**DISCUSSION**

The present study showed that VPA, as a class I selective histone deacetylase inhibitor, suppressed the growth of breast cancer MCF-7 cells, induced apoptosis, and arrested G1 phase of MCF-7 cells. Intrinsic apoptotic pathway, marked as caspase-3 and caspase-9 activity elevation, was responsible for VPA-induced apoptosis. Further G1 phase arrest, p21 up-regulation, and cyclin D1 down-regulation may be the main molecules involved. Our data provided the theoretical support for VPA as an antitumor drug in breast cancer treatment.

The existing studies provided evidence that a HDAC inhibitor could suppress tumor cell proliferation, mainly reflected in inhibition of cell growth vigor (21), apoptosis induction (22), cell proliferation cycle arrest (23), and tumor cell re-differentiation induction (24). In the present study, we explored the role of sodium valproate on breast cancer MCF-7 cells, including cell growth, apoptosis, and proliferation. By applications of different concentrations of sodium valproate, we determined the decrease in cell viabilities, which suggested the sodium valproate-induced inhibition of MCF-7 cell growth. Our results showed that the cell viability changed in a sodium valproate time- and concentration-dependent manner. Additionally, the concentration for VPA used in this study was in mM range, which is reported to induce hepatotoxicity in cultured HepG2 by leading to mitochondrial respiration dysfunction (25). However, for antitumor function, 0-350 µM concentration of the VPA compounds was not reported to induce any significant inhibition of MCF-7 cells, which indirectly indicated that the VPA level needed for in MCF-7 cells inhibition had to be in mM range (15). The concentration used on Hela cells in that study was also in mM range (15). Therefore, we inferred that mM level of VPA was needed for anti-breast cancer effect. However, this concentration adversely affects the liver function.

For cell apoptosis detection, we used low cytometry to determine the apoptosis ratios based on a series of different sodium valproate concentrations. The apoptotic rates obviously increased with increasing sodium valproate doses, which confirmed the induction of apoptosis by sodium valproate. Further, we explored the molecular mechanism involved in sodium valproate-induced apoptosis. Caspase was the central component of apoptosis, and caspase cascade was the actuator of apoptosis. Based on its role in apoptosis, caspase family was divided into the starting-type caspases (such as caspase-8 and caspase-9) and the effect-type caspases (such as caspase-1, caspase-3, caspase-6, and caspase-7). The activation of effect-type caspase acted on the respective substrates, inducing apoptosis characterized as DNA fragmentation at the nucleosome. According to the different component of caspase, cell apoptosis pathway was divided into extracellular pathway (death receptor pathway) and intrinsic apoptotic pathway (mitochondrial pathway) (26). Caspase-9 and caspase-3 are two impor-
Valproic acid in the growth of breast cancer MCF-7 cells

In summary, our results indicate that VPA's effect on MCF-7 cells includes inhibit cell growth, apoptosis induction, and G1 phase arrest. The mechanism underlying the effect on apoptosis induction involves the intracellular pathways (mitochondrial pathway). The mechanism underlying VPA effect on the cell cycle arrest in G1 phase induction include up-regulation of p21 mRNA and protein expression, which can bind CDKs competitively with cyclins, thus reducing the cyclin-CDK complexes and inducing G1 phrase arrest. Due to down-regulation of cyclin D1, mRNA, and protein expression inhibiting cyclin D1-CDK4/CDK6 pathway activity, cells cannot pass through the G1/S check point.

Funding This work was supported by the financial support of the Natural Science Foundation of Shandong Province (No. ZR2009CL017, No. ZR2013HQ055).

Ethical approval not required

Declaration of authorship XZ designed the experiments, wrote the manuscript and performed manuscript revision. XJM and WPG performed the experiments and participated in drafting the manuscript. XJM and WPG collected and analyzed the data and performed manuscript revision. All the authors approved the final version of the manuscript and agreed to be accountable for all aspects of the work.

Competing interests All authors have completed the Unified Competing Interest form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: no support from any organization that might have an interest in the submitted work in the previous 3 years; no other relationships or activities that could appear to have influenced the submitted work.

References

1. Sincennes MC, Brun CE, Rudnicki MA. Concise review: epigenetic regulation of myogenesis in health and disease. Stem Cells Transl Med. 2016;5:282-90. Medline:26798058 doi:10.5966/sctm.2015-0266

2. Chen HP, Zhao YT, Zhao TC. Histone deacetylases and mechanisms of regulation of gene expression. Crit Rev Oncog. 2015;20:335-47. Medline:25746103 doi:10.1016/j.critrevonc.2015.01.002

3. Haery L, Thompson RC, Gilmore TD. Histone acetyltransferases and histone deacetylases in B- and T-cell development, physiology and malignancy. Genes Cancer. 2015;6:184-213. Medline:26124919

4. Yang H, Salz T, Zajac-Kaye M, Liao D, Huang S, Qiu Y. Overexpression of histone deacetylases in cancer cells is controlled by interplay of transcription factors and epigenetic modulators. FASEB J. 2014;28:4265-79. Medline:24948597 doi:10.1096/fj.14-250654

5. Pang M, Zhuang S. Histone deacetylase: a potential therapeutic target for fibrotic disorders. J Pharmacol Exp Ther. 2010;335:266-72. Medline:20719940 doi:10.1124/jpet.110.168385

6. Xie C, Wu B, Chen B, Shi Q, Guo J, Fan Z, et al. Histone deacetylase inhibitor sodium butyrate suppresses proliferation and promotes apoptosis in osteosarcoma cells by regulation of the MDM2-p53 signaling. Onco Targets Ther. 2016;9:4005-13. Medline:27445491
BRAZILE W, KREHALLING JM, GEMMER J, MA Y, CRESS WD, HAURA E, et al. Histone deacetylase inhibitors downregulate checkpoint kinase 1 expression to induce cell death in non-small cell lung cancer cells. PLoS One. 2010;5:e14335. Medline:21179472 doi:10.1371/journal.pone.0014335

7 Hrgovic I, DOLL M, KLEEMANN J, WANG XF, ZOELLER N, PINTER A, et al. The histone deacetylase inhibitor trichostatin A decreases lymphangiogenesis by inducing apoptosis and cell cycle arrest via p21-dependent pathways. BMC Cancer. 2016;16:763. Medline:27716272 doi:10.1186/s12885-016-2807-y

8 Nagarška E, MATYA E, TARASZEWSKA A, RAFALOWSKA J. Protective effect of valproic acid on cultured motor neurons under glutamate excitotoxic conditions. Ultrastructural study. Folia Neuropathol. 2015;53:309-16. Medline:26783565 doi:10.5114/fn.2015.56545

9 Göttlicher M, MINUCCI S, ZHU P, KRAMER OH, SCHIMPF A, GIAVARA S, et al. Multiple mechanisms induce transcriptional silencing of subset of genes, including oestrogen-receptor alpha, in response to deacetylation inhibition by valproic acid and trichostatin A. Oncogene. 2005;24:4894-907. Medline:15870696 doi:10.1080/09502341003567215

10 Göttlicher M, Minucci S, Zhu P, Kramer OH, Schimpf A, Giavara S, et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J. 2001;20:6969-78. Medline:11472947 doi:10.1093/emboj/20.24.6969

11 Kwiecińska P, Wiśniewska J, Gregoraszczuk EŁ. Effects of valproic acid (VPA) and levetiracetam (LEV) on proliferation, apoptosis and hormone secretion of the human chorionic carcinoma BeWo cell line. Pharmacol Rep. 2011;63:1195-202. Medline:22180362 doi:10.1016/j.pharmretp.2011.05.058

12 HAJRA KM, LIU JR. Apoptosome dysfunction in human cancer. FEBS J. 2010;277:2-21. Medline:19843174 doi:10.1111/j.1742-4658.2009.07366.x

13 REID G, MÉTIVIER R, LIN CY, DENTER S, LIEBBERSON D, IVACEVIC T, et al. Multiple mechanisms induce transcriptional silencing of subset of genes, including oestrogen-receptor alpha, in response to deacetylation inhibition by valproic acid and trichostatin A. Oncogene. 2005;24:4894-907. Medline:15870696 doi:10.1038/sj.onc.1208662

14 BACERINO-BARBERO M, ROCA MS, ZOTTI AL, LEONE A, BRUZZESE F, VITAGLIANO C, et al. Valproic acid potentiates the anticancer activity of capetcitabine in vitro and in vivo in breast cancer models via induction of thymidine phosphorylase expression. Oncotarget. 2016;7:7715-31. Medline:26735339 doi:10.18632/oncotarget.6802

15 PRESTEGUI-MARTEL B, bERMÚDEZ-LUGO JA, CHÁVEZ-BLANCO A, GILARDINI MONTANI MS, GRANATO M, SANTONI C, DEL PORTO P, et al. Epigenetic priming of AML blasts for all-trans retinoic acid-induced differentiation by the HDAC class-I selective and TSA induce apoptosis and autophagy in pancreatic cancer cells. Cell Oncol (Dordr). 2013;36:167-80. Medline:23726914 doi:10.1007/s10020-013-0081-z

16 NAGARSKA E, MATYA E, TARASZEWSKA A, RAFALOWSKA J. Valproic acid inhibits proliferation of HER2-expressing breast cancer cells by inducing cell cycle arrest and apoptosis through Hsp70 acetylation. Int J Oncol. 2015;47:2073-81. Medline:26497673 doi:10.3892/ijt.2015.3213

17 KOMULAINEN T, LODGE T, HINTTALA R, BOLSZAK M, PIETILÄ M, KOIVUNEN P, et al. Sodium valproate induces mitochondrial respiration dysfunction in HepG2 in vitro cell model. Toxicology. 2015;332:100-6. Medline:25745980 doi:10.1016/j.tox.2015.03.001

18 TERRANOVA-BARBERO M, ROCA MS, ZOTTI AL, LEONE A, BRUZZESE F, VITAGLIANO C, et al. Valproic acid potentiates the anticancer activity of capetcitabine in vitro and in vivo in breast cancer models via induction of thymidine phosphorylase expression. Oncotarget. 2016;7:7715-31. Medline:26735339 doi:10.18632/oncotarget.6802

19 FORTUNATI N, BERTINO S, COSTANTINO L, BOSCO O, VERCELLINATO L, CATALANO MG, et al. Valproic acid is a selective antiproliferative agent in estrogen-sensitive breast cancer cells. Cancer Lett. 2008;259:156-64. Medline:18006146 doi:10.1016/j.canlet.2007.10.006

20 Kwiecińska P, Wiśniewska J, Gregoraszczuk EŁ. Effects of valproic acid (VPA) and levetiracetam (LEV) on proliferation, apoptosis and hormone secretion of the human chorionic carcinoma BeWo cell line. Pharmacol Rep. 2011;63:1195-202. Medline:22180362 doi:10.1016/j.pharmretp.2011.05.058

21 FISHER AD, WOODS TH, MANOCHA AK, VEDANTAM S, MILLER K, MASSEY E, et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J. 2001;20:6969-78. Medline:11472947 doi:10.1093/emboj/20.24.6969

22 Park KC, Heo JH, Jeon JV, Choi HJ, Jo AR, Kim SW, et al. The novel histone deacetylase inhibitor, N-hydroxy-7-(2-naphthyl)heptanomide, exhibits potent antitumor activity due to cytochrome-c-release-mediated apoptosis in renal cell carcinoma cells. BMC Cancer. 2015;15:19. Medline:26513585 doi:10.1186/s12885-014-1003-1

23 Mawatari T, NINOMIYA I, INOKUCHI M, HARADA S, HAYASHI H, OYAMA K, et al. Valproic acid inhibits proliferation of HER2-expressing breast cancer cells by inducing cell cycle arrest and apoptosis through Hsp70 acetylation. Int J Oncol. 2015;47:2073-81. Medline:26497673 doi:10.3892/ijt.2015.3213

24 LEE KY, CHUNG BY, KIM JH, KIM SW, et al. Valproic acid inhibits proliferation of HER2-expressing breast cancer cells by inducing cell cycle arrest and apoptosis through Hsp70 acetylation. Int J Oncol. 2015;47:2073-81. Medline:26497673 doi:10.3892/ijt.2015.3213

25 REID G, METIVIER R, LIN CY, DENTER S, LIEBBERSON D, IVACEVIC T, et al. Multiple mechanisms induce transcriptional silencing of subset of genes, including oestrogen-receptor alpha, in response to deacetylation inhibition by valproic acid and trichostatin A. Oncogene. 2005;24:4894-907. Medline:15870696 doi:10.1038/sj.onc.1208662

26 SANG Z, SUN Y, Ruan H, Cheng Y, Ding X, Yu Y. Anticancer effects of valproic acid on oral squamous cell carcinoma via SUMOylation in vivo and in vitro. Exp Ther Med. 2016;12:3979-87. Medline:28101176 doi:10.3892/etm.2016.3907

27 TERRANOVA-BARBERO M, ROCA MS, ZOTTI AL, LEONE A, BRUZZESE F, VITAGLIANO C, et al. Valproic acid potentiates the anticancer activity of capetcitabine in vitro and in vivo in breast cancer models via induction of thymidine phosphorylase expression. Oncotarget. 2016;7:7715-31. Medline:26735339 doi:10.18632/oncotarget.6802

28 FORTUNATI N, BERTINO S, COSTANTINO L, BOSCO O, VERCELLINATO L, CATALANO MG, et al. Valproic acid is a selective antiproliferative agent in estrogen-sensitive breast cancer cells. Cancer Lett. 2008;259:156-64. Medline:18006146 doi:10.1016/j.canlet.2007.10.006

29 Yang W, Zhao X, Pei F, Ji M, Ma W, Wang Y, et al. Activation of the intrinsic apoptosis pathway contributes to the induction of apoptosis in hepatocellular carcinoma cells by valproic acid. Oncol Lett. 2015;9:881-6. Medline:25621063

30 Garrett LA, Growdon WB, Rueda BR, Foster R. Influence of a novel histone deacetylase inhibitor panobinostat (LBH589) on the growth of ovarian cancer. J Ovarian Res. 2016;9:58. Medline:27633667 doi:10.1186/s13048-016-0267-2
28 Singh TR, Shankar S, Srivastava RK. HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma. Oncogene. 2005;24:4609-23. Medline:15897906 doi:10.1038/sj.onc.1208585

29 Shieh JM, Wei TT, Tang YA, Huang SM, Wen WL, Chen MY, et al. Mitochondrial apoptosis and FAK signaling disruption by a novel histone deacetylase inhibitor, HTP8, in antitumor and antimetastatic mouse models. PLoS One. 2012;7:e30240. Medline:22279574 doi:10.1371/journal.pone.0030240

30 Zakana S, Gamal-Eldeen AM, El-Daly SM, Saleh S. Synergistic apoptotic effect of Doxil® and aminolevulinic acid-based photodynamic therapy on human breast adenocarcinoma cells. Photodiagnosis Photodyn Ther. 2014;11:227-38. Medline:24632331 doi:10.1016/j.pdpdt.2014.03.001

31 Singh RP, Agarwal R. Natural flavonoids targeting deregulated cell cycle progression in cancer cells. Curr Drug Targets. 2006;7:345-54. Medline:16515531 doi:10.2174/138945006776055004

32 Cinafit J Jr, Kotchetkov R, Blaheta R, Driever PH, Vogel JU, Cinafit J. Induction of differentiation and suppression of malignant phenotype of human neuroblastoma BE (2)-C cells by valproic acid: enhancement by combination with interferon α. Int J Oncol. 2002;20:97-106. Medline:11743648

33 Bacon CL, Gallagher HC, Haughey JC, Regan CM. Antiproliferative action of valproate is associated with aberrant expression and nuclear translocation of cyclin D3 during the C6 glioma G1 phase. J Neurochem. 2002;83:12-9. Medline:12358724 doi:10.1046/j.1471-4159.2002.01081.x

34 Park HY, Kim MK, Moon SJ, Cho YH, Lee CH. Cell cycle arrest and apoptotic induction in LNCaP cells by MCS-C2, novel cyclin-dependent kinase inhibitor, through p53/p21/WAF1/CIP1 pathway. Cancer Sci. 2006;97:430-6. Medline:16630142 doi:10.1111/j.1349-7006.2006.00195.x